ustekinumab vs ustekinumab-ttwe (Pyzchiva)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: IL-12 p40 · full Ulcerative Colitis pipeline
ustekinumab · Stelara
Marketed by Johnson & Johnson
NCT02407236 · Phase 3 · completed
Randomized, double-blind, placebo-controlled, adequately powered (n=961) Phase 3 trial with clinical remission (Mayo score-based, including endoscopic subscore) as the primary endpoint, and the primary comparisons were statistically significant in the favorable direction for both induction and maintenance phases (p<0.001 to p=0.002).
Next expected readout: April 2027 · NCT07303686 (registry estimate)
Reported efficacy
Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per Global Definition); Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per US Definition); Maintenance Study: Number of Participants With Clinical Remission at Week 44 (As Per Global Definition); Maintenance Study: Number of Participants With Clinical Remission at Week 44 (as Per US Definition): Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per Global Definition) (Week 8): Induction Study (IS): Placebo Intravenous (IV) 17/319 (5.3%) vs IS: Ustekinumab 130 Milligram (mg) IV 50/320 (15.6%) vs IS: Ustekinumab Approximately 6 mg/kg IV 50/322 (15.5%); p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab 130 Milligram (mg) IV), p=< 0.001 (Induction Study (IS): Placebo Intravenous (IV) vs IS: Ustekinumab Approximately 6 mg/kg IV) (met)
Result source: NCT02407236
ustekinumab-ttwe (Pyzchiva)
Marketed by Samsung Bioepis and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ustekinumab | ustekinumab-ttwe (Pyzchiva) |
|---|---|---|
| Clinical remission (induction) | 15.6% vs 5.3%+10.3 vs placeboNCT024072363 other results
| —Not reported |
| Clinical remission (maintenance) | 43.8% vs 24%+19.8 vs placeboNCT024072363 other results
| —Not reported |
| Clinical response (induction) | 51.3% vs 31.3%+20 vs placeboNCT024072361 other result
| —Not reported |
| Endoscopic improvement (induction) | —Trial running · NCT05092269 | —Not reported |
| Corticosteroid-free remission (maintenance) | 42% vs 23.4%+18.6 vs placeboNCT024072363 other results
| —Not reported |
Clinical remission (induction)
- ustekinumab
- 15.6% vs 5.3%+10.3 vs placeboNCT02407236
3 other results
- 16.6% vs 6.3% NCT02407236
- 15.5% vs 5.3% NCT02407236
- 18.9% vs 6.3% NCT02407236
- ustekinumab-ttwe (Pyzchiva)
- —Not reported
Clinical remission (maintenance)
- ustekinumab
- 43.8% vs 24%+19.8 vs placeboNCT02407236
3 other results
- 42.6% vs 24.6% NCT02407236
- 38.4% vs 24% NCT02407236
- 39.5% vs 24.6% NCT02407236
- ustekinumab-ttwe (Pyzchiva)
- —Not reported
Clinical response (induction)
- ustekinumab
- 51.3% vs 31.3%+20 vs placeboNCT02407236
1 other result
- 61.8% vs 31.3% NCT02407236
- ustekinumab-ttwe (Pyzchiva)
- —Not reported
Endoscopic improvement (induction)
- ustekinumab
- —Trial running · NCT05092269
- ustekinumab-ttwe (Pyzchiva)
- —Not reported
Corticosteroid-free remission (maintenance)
- ustekinumab
- 42% vs 23.4%+18.6 vs placeboNCT02407236
3 other results
- 40.9% vs 24% NCT02407236
- 37.8% vs 23.4% NCT02407236
- 39% vs 24% NCT02407236
- ustekinumab-ttwe (Pyzchiva)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ustekinumab-ttwe (Pyzchiva): no structured comparison results are available for Ulcerative Colitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ustekinumab: 4 of 4 rows · ustekinumab-ttwe (Pyzchiva): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | ustekinumab |
|---|---|
| Dropout rate | —90 mg SC q8w NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 show 10 more results—90 mg SC q8w NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 —90 mg SC q8w NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 —90mg SC q8w NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 —90mg SC every 8 weeks (q8w) NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 —90mg SC q8w NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 3.4%130 mg IV NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 —90 mg SC q12w NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 —90 mg SC q12w to 90 mg SC q8w NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 —90mg SC every 12 weeks (q12w) NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 4.7%approximately 6mg/kg IV NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 |
| Discontinued due to AEs | —90 mg SC q8w NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 show 10 more results—90 mg SC q8w NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 —90 mg SC q8w NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 —90mg SC q8w NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 —90mg SC every 8 weeks (q8w) NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 —90mg SC q8w NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 0%130 mg IV NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 —90 mg SC q12w NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 —90 mg SC q12w to 90 mg SC q8w NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 —90mg SC every 12 weeks (q12w) NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 0.3%approximately 6mg/kg IV NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 |
| Serious AEs | 14.3%90 mg SC q8w NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 show 10 more results10.5%90 mg SC q8w NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 8.1%90 mg SC q8w NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 12.1%90mg SC q8w NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 8.5%90mg SC every 8 weeks (q8w) NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 7%90mg SC q8w NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 3.7%130 mg IV NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 9.2%90 mg SC q12w NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 9.4%90 mg SC q12w to 90 mg SC q8w NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 7.6%90mg SC every 12 weeks (q12w) NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 3.4%approximately 6mg/kg IV NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 |
| Most frequent reported AEs | 90 mg SC q8w nasopharyngitis 23.2% (placebo 2.8%) colitis ulcerative 19.6% (placebo 2.5%) alanine aminotransferase increased 12.5% (placebo 0.6%) NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 show 10 more results90 mg SC q8w colitis ulcerative 25.9% (placebo 2.5%) nasopharyngitis 18.9% (placebo 2.8%) upper respiratory tract infection 11.9% (placebo 1.3%) NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 90 mg SC q8w colitis ulcerative 35.1% (placebo 2.5%) nasopharyngitis 32.4% (placebo 2.8%) sinusitis 10.8% (placebo 0.3%) NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 90mg SC q8w nasopharyngitis 27.6% (placebo 2.8%) colitis ulcerative 25.9% (placebo 2.5%) headache 9.5% (placebo 4.4%) NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 90mg SC every 8 weeks (q8w) nasopharyngitis 14.8% (placebo 2.8%) headache 10.2% (placebo 4.4%) colitis ulcerative 9.1% (placebo 2.5%) NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 90mg SC q8w colitis ulcerative 14.6% (placebo 2.5%) nasopharyngitis 12.1% (placebo 2.8%) arthralgia 10.2% (placebo 0.9%) NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 130 mg IV headache 6.9% (placebo 4.4%) nasopharyngitis 4% (placebo 2.8%) abdominal pain 2.5% (placebo 2.8%) NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 90 mg SC q12w colitis ulcerative 24.1% (placebo 2.5%) nasopharyngitis 20.6% (placebo 2.8%) upper respiratory tract infection 8.5% (placebo 1.3%) NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 90 mg SC q12w to 90 mg SC q8w colitis ulcerative 31.3% (placebo 2.5%) nasopharyngitis 15.6% (placebo 2.8%) arthralgia 7.8% (placebo 0.9%) NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 90mg SC every 12 weeks (q12w) nasopharyngitis 18% (placebo 2.8%) colitis ulcerative 11% (placebo 2.5%) arthralgia 9.3% (placebo 0.9%) NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 approximately 6mg/kg IV nasopharyngitis 5.6% (placebo 2.8%) headache 4.1% (placebo 4.4%) anaemia 2.5% (placebo 3.4%) NCT02407236 · Phase 3 · Ulcerative Colitis · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
ustekinumab
show 7 more results
show 3 more results
show 3 more results
show 5 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 5 more results
show 49 more results
show 1 more result
show 1 more result
Crohn's Disease
Shared mechanism: IL-12 p40 · full Crohn's Disease pipeline
ustekinumab · Stelara
Marketed by Johnson & Johnson
NCT01369329 · Phase 3 · completed
Randomized, quadruple-blinded, placebo-controlled, adequately powered (n~741) Phase 3 trial with a clinical primary endpoint (CDAI-based response), and the primary comparison for both active doses reached statistical significance in the favorable direction versus placebo, satisfying the 'strong' definition.
Next expected readout: December 2026 · NCT06520397 (registry estimate)
Reported efficacy
Number of Participants With Clinical Remission at Week 44: Number of Participants With Clinical Remission at Week 44 (Week 44): Placebo Subcutaneously (SC) 47/131 (35.9%) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w) 63/129 (48.8%) vs Ustekinumab 90 mg SC q8w 68/128 (53.1%); p=0.040 (Placebo Subcutaneously (SC) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w)), p=0.005 (Placebo Subcutaneously (SC) vs Ustekinumab 90 mg SC q8w) (met)
Result source: NCT01369355
ustekinumab-ttwe (Pyzchiva)
Marketed by Samsung Bioepis and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ustekinumab | ustekinumab-ttwe (Pyzchiva) |
|---|---|---|
| Clinical remission (induction) | 15.9% vs 7.3%+8.6 vs placeboNCT0136932915 other results
| —Not reported |
| Endoscopic response (induction) | —Not posted · NCT05299931 | —Not reported |
| Clinical remission (maintenance) | 53.1% vs 35.9%+17.2 vs placeboNCT013693556 other results
| —Not reported |
| Endoscopic response (maintenance) | 23.5% vs 16%vs UstekinumabNCT04245215 | —Not reported |
Clinical remission (induction)
- ustekinumab
- 15.9% vs 7.3%+8.6 vs placeboNCT01369329
15 other results
- 30.6% vs 19.6% NCT01369342
- 20.9% vs 7.3% NCT01369329
- 40.2% vs 19.6% NCT01369342
- 35.8% vs 38.9% NCT04245215
- 18.3% vs 10.6% NCT00771667
- 12.2% vs 10.6% NCT00771667
- 18.2% vs 10.6% NCT00771667
- 15.9% vs 10.6% NCT00771667
- 17.6% vs 10.6% NCT00771667
- 16% vs 10.6% NCT00771667
- 24% vs 11.1% NCT00265122
- 26.9% vs 11.1% NCT00265122
- 30% vs 14.6% NCT02877134
- 18.4% vs 14.6% NCT02877134
- 22.4% vs 14.6% NCT02877134
- ustekinumab-ttwe (Pyzchiva)
- —Not reported
Endoscopic response (induction)
- ustekinumab
- —Not posted · NCT05299931
- ustekinumab-ttwe (Pyzchiva)
- —Not reported
Clinical remission (maintenance)
- ustekinumab
- 53.1% vs 35.9%+17.2 vs placeboNCT01369355
6 other results
- 48.8% vs 35.9% NCT01369355
- 66.7% vs 45.6% NCT01369355
- 41.1% vs 26.2% NCT01369355
- 56.4% vs 45.6% NCT01369355
- 38.6% vs 26.2% NCT01369355
- 30.8% vs 36% NCT04245215
- ustekinumab-ttwe (Pyzchiva)
- —Not reported
Endoscopic response (maintenance)
- ustekinumab
- 23.5% vs 16%vs UstekinumabNCT04245215
- ustekinumab-ttwe (Pyzchiva)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ustekinumab-ttwe (Pyzchiva): no structured comparison results are available for Crohn's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ustekinumab: 4 of 4 rows · ustekinumab-ttwe (Pyzchiva): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | ustekinumab |
|---|---|
| Dropout rate | 4.3%130 mga NCT01369329 · Phase 3 · Crohn's Disease · phase 3 show 37 more results5.4%~6 mg/kg NCT01369329 · Phase 3 · Crohn's Disease · phase 3 4.2%130 mg NCT01369342 · Phase 3 · Crohn's Disease · phase 3 1.4%~6 mg/kg NCT01369342 · Phase 3 · Crohn's Disease · phase 3 —90 mg SC Q8W NCT01369355 · Phase 3 —90 mg SC Q8W NCT01369355 · Phase 3 —130 mg IV / 90 mg SC Q12W NCT01369355 · Phase 3 —90 mg SC Q12W NCT01369355 · Phase 3 —90 mg SC Q8W NCT01369355 · Phase 3 —90 mg SC Q8W NCT01369355 · Phase 3 —90 mg SC Q12W NCT01369355 · Phase 3 —90 mg SC Q12W/Q8W NCT01369355 · Phase 3 31.5%q4w NCT04245215 · Phase 3 · monotherapy · Crohn's Disease · phase 3 24.1%IV re-induction NCT03782376 · Phase 3 · combination · Crohn's Disease · phase 3 28%q8w SC maintenance NCT03782376 · Phase 3 · Crohn's Disease · phase 3 —Extension Period: Routine Care NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —Extension Period: Treat to Target NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —Maintenance Period: Routine Care NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —Maintenance Period: Treat to Targe NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3 4%IV NCT04673357 · Phase 3 —SC q12w NCT04673357 · Phase 3 —SC q8w NCT04673357 · Phase 3 34.2%Part I: JNJ-64304500 NCT02877134 · Phase 2 · registry result, not featured evidence —High Dose NCT02877134 · Phase 2 · registry result, not featured evidence —Low Dose NCT02877134 · Phase 2 · registry result, not featured evidence —Middle Dose NCT02877134 · Phase 2 · registry result, not featured evidence 20.4%High Dose NCT02877134 · Phase 2 · registry result, not featured evidence 30%Low Dose NCT02877134 · Phase 2 · registry result, not featured evidence 14.3%Middle Dose NCT02877134 · Phase 2 · registry result, not featured evidence —90 mg SC NCT00771667 · Phase 2 · registry result, not featured evidence —90 mg SC NCT00771667 · Phase 2 · registry result, not featured evidence 6.1%6 mg/kg IV NCT00771667 · Phase 2 · registry result, not featured evidence 9.1%3 mg/kg IV NCT00771667 · Phase 2 · registry result, not featured evidence 7.6%1 mg/kg IV NCT00771667 · Phase 2 · registry result, not featured evidence 8%90 mg SC NCT00265122 · Phase 2 · registry result, not featured evidence 7.1%90 mg SC NCT00265122 · Phase 2 · registry result, not featured evidence 7.7%4.5 mg/kg IV NCT00265122 · Phase 2 · registry result, not featured evidence 0%4.5 mg/kg IV NCT00265122 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —130 mga NCT01369329 · Phase 3 · Crohn's Disease · phase 3 show 37 more results—~6 mg/kg NCT01369329 · Phase 3 · Crohn's Disease · phase 3 —130 mg NCT01369342 · Phase 3 · Crohn's Disease · phase 3 —~6 mg/kg NCT01369342 · Phase 3 · Crohn's Disease · phase 3 —90 mg SC Q8W NCT01369355 · Phase 3 —90 mg SC Q8W NCT01369355 · Phase 3 —130 mg IV / 90 mg SC Q12W NCT01369355 · Phase 3 —90 mg SC Q12W NCT01369355 · Phase 3 —90 mg SC Q8W NCT01369355 · Phase 3 —90 mg SC Q8W NCT01369355 · Phase 3 —90 mg SC Q12W NCT01369355 · Phase 3 —90 mg SC Q12W/Q8W NCT01369355 · Phase 3 —q4w NCT04245215 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —IV re-induction NCT03782376 · Phase 3 · combination · Crohn's Disease · phase 3 —q8w SC maintenance NCT03782376 · Phase 3 · Crohn's Disease · phase 3 —Extension Period: Routine Care NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —Extension Period: Treat to Target NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —Maintenance Period: Routine Care NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —Maintenance Period: Treat to Targe NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3 3%IV NCT04673357 · Phase 3 —SC q12w NCT04673357 · Phase 3 —SC q8w NCT04673357 · Phase 3 —Part I: JNJ-64304500 NCT02877134 · Phase 2 · registry result, not featured evidence —High Dose NCT02877134 · Phase 2 · registry result, not featured evidence —Low Dose NCT02877134 · Phase 2 · registry result, not featured evidence —Middle Dose NCT02877134 · Phase 2 · registry result, not featured evidence —High Dose NCT02877134 · Phase 2 · registry result, not featured evidence —Low Dose NCT02877134 · Phase 2 · registry result, not featured evidence —Middle Dose NCT02877134 · Phase 2 · registry result, not featured evidence —90 mg SC NCT00771667 · Phase 2 · registry result, not featured evidence —90 mg SC NCT00771667 · Phase 2 · registry result, not featured evidence 0.8%6 mg/kg IV NCT00771667 · Phase 2 · registry result, not featured evidence 3%3 mg/kg IV NCT00771667 · Phase 2 · registry result, not featured evidence 1.5%1 mg/kg IV NCT00771667 · Phase 2 · registry result, not featured evidence —90 mg SC NCT00265122 · Phase 2 · registry result, not featured evidence —90 mg SC NCT00265122 · Phase 2 · registry result, not featured evidence —4.5 mg/kg IV NCT00265122 · Phase 2 · registry result, not featured evidence —4.5 mg/kg IV NCT00265122 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 5.5%130 mga NCT01369329 · Phase 3 · Crohn's Disease · phase 3 show 37 more results6.9%~6 mg/kg NCT01369329 · Phase 3 · Crohn's Disease · phase 3 4.6%130 mg NCT01369342 · Phase 3 · Crohn's Disease · phase 3 4.3%~6 mg/kg NCT01369342 · Phase 3 · Crohn's Disease · phase 3 28%90 mg SC Q8W NCT01369355 · Phase 3 9.9%90 mg SC Q8W NCT01369355 · Phase 3 16.5%130 mg IV / 90 mg SC Q12W NCT01369355 · Phase 3 31.9%90 mg SC Q12W NCT01369355 · Phase 3 20.7%90 mg SC Q8W NCT01369355 · Phase 3 16.2%90 mg SC Q8W NCT01369355 · Phase 3 12.1%90 mg SC Q12W NCT01369355 · Phase 3 17.2%90 mg SC Q12W/Q8W NCT01369355 · Phase 3 16.7%q4w NCT04245215 · Phase 3 · monotherapy · Crohn's Disease · phase 3 8.3%IV re-induction NCT03782376 · Phase 3 · combination · Crohn's Disease · phase 3 12.1%q8w SC maintenance NCT03782376 · Phase 3 · Crohn's Disease · phase 3 13.1%Extension Period: Routine Care NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3 14.3%Extension Period: Treat to Target NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3 13.1%Maintenance Period: Routine Care NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3 11.9%Maintenance Period: Treat to Targe NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3 3%IV NCT04673357 · Phase 3 12.2%SC q12w NCT04673357 · Phase 3 14.6%SC q8w NCT04673357 · Phase 3 11%Part I: JNJ-64304500 NCT02877134 · Phase 2 · registry result, not featured evidence 20.8%High Dose NCT02877134 · Phase 2 · registry result, not featured evidence 9.5%Low Dose NCT02877134 · Phase 2 · registry result, not featured evidence 18.5%Middle Dose NCT02877134 · Phase 2 · registry result, not featured evidence 12.2%High Dose NCT02877134 · Phase 2 · registry result, not featured evidence 6%Low Dose NCT02877134 · Phase 2 · registry result, not featured evidence 0%Middle Dose NCT02877134 · Phase 2 · registry result, not featured evidence 20.2%90 mg SC NCT00771667 · Phase 2 · registry result, not featured evidence 12.5%90 mg SC NCT00771667 · Phase 2 · registry result, not featured evidence 6.9%6 mg/kg IV NCT00771667 · Phase 2 · registry result, not featured evidence 6%3 mg/kg IV NCT00771667 · Phase 2 · registry result, not featured evidence 4.6%1 mg/kg IV NCT00771667 · Phase 2 · registry result, not featured evidence 4%90 mg SC NCT00265122 · Phase 2 · registry result, not featured evidence 14.3%90 mg SC NCT00265122 · Phase 2 · registry result, not featured evidence 11.1%4.5 mg/kg IV NCT00265122 · Phase 2 · registry result, not featured evidence 15.4%4.5 mg/kg IV NCT00265122 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 130 mga arthralgia 11% (placebo 7.5%) headache 7.8% (placebo 8.7%) nausea 7.8% (placebo 7.1%) NCT01369329 · Phase 3 · Crohn's Disease · phase 3 show 37 more results~6 mg/kg headache 7.7% (placebo 8.7%) arthralgia 5.8% (placebo 7.5%) nausea 5.8% (placebo 7.1%) NCT01369329 · Phase 3 · Crohn's Disease · phase 3 130 mg headache 9.3% (placebo 6.6%) nasopharyngitis 4.6% (placebo 4.7%) nausea 3.2% (placebo 2.4%) NCT01369342 · Phase 3 · Crohn's Disease · phase 3 ~6 mg/kg nasopharyngitis 6.6% (placebo 4.7%) nausea 5.2% (placebo 2.4%) pyrexia 5.2% (placebo 4.7%) NCT01369342 · Phase 3 · Crohn's Disease · phase 3 90 mg SC Q8W nasopharyngitis 28.2% (placebo 12.2%) crohn's disease 22.6% (placebo 10.6%) abdominal pain 19.2% (placebo 12.2%) NCT01369355 · Phase 3 90 mg SC Q8W arthralgia 13.7% (placebo 18.7%) headache 11.5% (placebo 13%) nasopharyngitis 10.7% (placebo 12.2%) NCT01369355 · Phase 3 130 mg IV / 90 mg SC Q12W nasopharyngitis 11.2% (placebo 12.2%) arthralgia 10.2% (placebo 18.7%) upper respiratory tract infection 8.8% (placebo 5.7%) NCT01369355 · Phase 3 90 mg SC Q12W nasopharyngitis 25.4% (placebo 12.2%) crohn's disease 20.7% (placebo 10.6%) upper respiratory tract infection 18.8% (placebo 5.7%) NCT01369355 · Phase 3 90 mg SC Q8W arthralgia 10.3% (placebo 18.7%) back pain 10.3% (placebo 1.6%) abdominal pain upper 6.9% (placebo 4.1%) NCT01369355 · Phase 3 90 mg SC Q8W nasopharyngitis 10.9% (placebo 12.2%) arthralgia 10.3% (placebo 18.7%) nausea 9.7% (placebo 9.8%) NCT01369355 · Phase 3 90 mg SC Q12W arthralgia 16.7% (placebo 18.7%) nasopharyngitis 12.9% (placebo 12.2%) headache 11.4% (placebo 13%) NCT01369355 · Phase 3 90 mg SC Q12W/Q8W abdominal pain 17.2% (placebo 12.2%) arthralgia 17.2% (placebo 18.7%) nasopharyngitis 13.8% (placebo 12.2%) NCT01369355 · Phase 3 q4w respiratory infection 38.9% musculoskeletal and connective tissue disorders 33.3% abdominal pain 18.5% NCT04245215 · Phase 3 · monotherapy · Crohn's Disease · phase 3 IV re-induction crohn's disease 21.3% covid-19 11.1% headache 7.4% NCT03782376 · Phase 3 · combination · Crohn's Disease · phase 3 q8w SC maintenance crohn's disease 27.1% covid-19 15% cough 5.6% NCT03782376 · Phase 3 · Crohn's Disease · phase 3 nasopharyngitis 19.9% headache 15.9% arthralgia 14.8% NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3 arthralgia 16.3% abdominal pain 15.6% nasopharyngitis 15.6% NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3 nasopharyngitis 13.1% crohn's disease 9.5% headache 9.5% NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3 nasopharyngitis 13.2% pyrexia 11.4% arthralgia 11% NCT03107793 · Phase 3 · monotherapy · Crohn's Disease · phase 3 SC q12w crohn's disease 32.7% upper respiratory tract infection 32.7% anaemia 14.3% NCT04673357 · Phase 3 SC q8w crohn's disease 37.5% covid-19 16.7% upper respiratory tract infection 14.6% NCT04673357 · Phase 3 anaemia 12.3% (placebo 4.2%) headache 11% (placebo 6.9%) lymphocyte count decreased 9.6% (placebo 2.8%) NCT02877134 · Phase 2 · registry result, not featured evidence High Dose back pain 8.3% (placebo 0%) crohn's disease 8.3% (placebo 5.6%) pyrexia 8.3% (placebo 1.4%) NCT02877134 · Phase 2 · registry result, not featured evidence Low Dose rash 9.5% (placebo 0%) abdominal pain 4.8% (placebo 4.2%) back pain 4.8% (placebo 0%) NCT02877134 · Phase 2 · registry result, not featured evidence Middle Dose crohn's disease 14.8% (placebo 5.6%) anaemia 11.1% (placebo 4.2%) nasopharyngitis 11.1% (placebo 4.2%) NCT02877134 · Phase 2 · registry result, not featured evidence High Dose rhinitis 10.2% (placebo 0%) headache 8.2% (placebo 6.9%) nasopharyngitis 8.2% (placebo 4.2%) NCT02877134 · Phase 2 · registry result, not featured evidence Low Dose anaemia 12% (placebo 4.2%) crohn's disease 8% (placebo 5.6%) nasopharyngitis 6% (placebo 4.2%) NCT02877134 · Phase 2 · registry result, not featured evidence Middle Dose anaemia 14.3% (placebo 4.2%) crohn's disease 14.3% (placebo 5.6%) headache 8.2% (placebo 6.9%) NCT02877134 · Phase 2 · registry result, not featured evidence 90 mg SC crohn's disease 9.2% (placebo 6.1%) headache 7.3% (placebo 6.1%) abdominal pain 6.4% (placebo 6.8%) NCT00771667 · Phase 2 · registry result, not featured evidence 90 mg SC crohn's disease 9.7% (placebo 6.1%) nausea 9.7% (placebo 8.3%) upper respiratory tract infection 8.3% (placebo 0%) NCT00771667 · Phase 2 · registry result, not featured evidence 6 mg/kg IV headache 9.9% (placebo 6.1%) nasopharyngitis 6.1% (placebo 4.5%) nausea 6.1% (placebo 8.3%) NCT00771667 · Phase 2 · registry result, not featured evidence 3 mg/kg IV headache 6.8% (placebo 6.1%) abdominal pain 6% (placebo 6.8%) arthralgia 6% (placebo 3%) NCT00771667 · Phase 2 · registry result, not featured evidence 1 mg/kg IV nausea 6.9% (placebo 8.3%) arthralgia 6.2% (placebo 3%) headache 6.2% (placebo 6.1%) NCT00771667 · Phase 2 · registry result, not featured evidence 90 mg SC headache 24% (placebo 15.8%) arthralgia 20% (placebo 15.8%) upper respiratory tract infection 20% (placebo 15.8%) NCT00265122 · Phase 2 · registry result, not featured evidence 90 mg SC crohn's disease 28.6% (placebo 21.1%) headache 21.4% (placebo 15.8%) nausea 21.4% (placebo 10.5%) NCT00265122 · Phase 2 · registry result, not featured evidence 4.5 mg/kg IV crohn's disease 25.9% (placebo 21.1%) abdominal pain 18.5% (placebo 0%) headache 14.8% (placebo 15.8%) NCT00265122 · Phase 2 · registry result, not featured evidence 4.5 mg/kg IV crohn's disease 30.8% (placebo 21.1%) gastroenteritis viral 23.1% (placebo 10.5%) headache 23.1% (placebo 15.8%) NCT00265122 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 27 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
ustekinumab
show 21 more results
show 23 more results
show 3 more results
show 3 more results
show 1 more result
show 9 more results
show 13 more results
+ 23 further endpoints in the CSV export.
Psoriasis
Shared mechanism: IL-12 p40 · full Psoriasis pipeline
ustekinumab · Stelara
Marketed by Johnson & Johnson
NCT00307437 · Phase 3 · completed
This was a large (1,230-patient), randomized, blinded, placebo-controlled trial with a validated skin-clearance measure (PASI 75) as its primary endpoint, and both ustekinumab doses beat placebo by a wide, statistically significant margin (p<0.001).
Next expected readout: December 2026 · NCT05270733 (registry estimate)
Reported efficacy
Number of Participants With Psoriasis Area and Severity Index (PASI) Score of 75 Percent or Above at Week 12 (Week 0 to Week 12): PASI 75 at Week 12 (intent-to-treat, PHOENIX 2 trial): placebo 15/410 vs ustekinumab 45 mg 273/409 vs ustekinumab 90 mg 311/411; p<0.001 for each dose vs placebo. (met)
Result source: NCT00307437
ustekinumab-ttwe (Pyzchiva)
Marketed by Samsung Bioepis and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ustekinumab | ustekinumab-ttwe (Pyzchiva) |
|---|---|---|
| PASI 75 | 75.7% vs 3.7%+72 vs placeboNCT0030743718 other results
| —Not reported |
| PASI 90 | 54.1% vs 5.4%+48.7 vs placeboNCT010904273 other results
| —Not reported |
| PASI 100 | 29.9% vs 26.2%vs UstekinumabNCT046079802 other results
| —Not reported |
| sPGA 0/1 | 67.6% vs 5.4%+62.2 vs placeboNCT0109042710 other results
| —Not reported |
| DLQI, change | -9 vs -0.5−8.5 vs placeboNCT003074377 other results
| —Not reported |
PASI 75
- ustekinumab
- 75.7% vs 3.7%+72 vs placeboNCT00307437
18 other results
- 66.4% vs 3.1% NCT00267969
- 66.7% vs 3.7% NCT00307437
- 67.1% vs 3.1% NCT00267969
- 67.7% vs 6.5% NCT00723528
- 82.5% vs 11.1% NCT01008995
- 59.4% vs 6.5% NCT00723528
- 67.2% vs 5% NCT00747344
- 73.8% vs 56.8% NCT00454584
- 67.5% vs 56.8% NCT00454584
- 78.4% vs 10.8% NCT01090427
- 80.6% vs 10.8% NCT01090427
- 80.8% vs 80.1% NCT04607980
- 69.8% vs 70.2% NCT04607980
- 11.4% vs 10.3% NCT04607980
- 59.4% vs 1.6% NCT00320216
- 81.3% vs 1.6% NCT00320216
- 51.6% vs 1.6% NCT00320216
- 67.2% vs 1.6% NCT00320216
- ustekinumab-ttwe (Pyzchiva)
- —Not reported
PASI 90
- ustekinumab
- 54.1% vs 5.4%+48.7 vs placeboNCT01090427
3 other results
- 61.1% vs 5.4% NCT01090427
- 44.7% vs 23.1% NCT00454584
- 36.4% vs 23.1% NCT00454584
- ustekinumab-ttwe (Pyzchiva)
- —Not reported
PASI 100
- ustekinumab
- 29.9% vs 26.2%vs UstekinumabNCT04607980
2 other results
- 20.6% vs 19.1% NCT04607980
- 0.4% vs 0.7% NCT04607980
- ustekinumab-ttwe (Pyzchiva)
- —Not reported
sPGA 0/1
- ustekinumab
- 67.6% vs 5.4%+62.2 vs placeboNCT01090427
10 other results
- 69.4% vs 5.4% NCT01090427
- 73% vs 4.4% NCT00307437
- 60.9% vs 3.9% NCT00267969
- 67.7% vs 4.4% NCT00307437
- 59.2% vs 3.9% NCT00267969
- 78.8% vs 14.8% NCT01008995
- 70.5% vs 8.3% NCT00747344
- 70.6% vs 49% NCT00454584
- 65.1% vs 49% NCT00454584
- 55.2% vs 52.8% NCT04607980
- ustekinumab-ttwe (Pyzchiva)
- —Not reported
DLQI, change
- ustekinumab
- -9 vs -0.5−8.5 vs placeboNCT00307437
7 other results
- -7 vs 0 NCT00267969
- -8 vs -0.5 NCT00307437
- -6 vs 0 NCT00267969
- -7.4 vs -0.3 NCT00723528
- -9.3 vs -1.9 NCT01008995
- -8 vs -0.3 NCT00723528
- -11.2 vs -0.5 NCT00747344
- ustekinumab-ttwe (Pyzchiva)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ustekinumab-ttwe (Pyzchiva): registry results are on file for Psoriasis, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ustekinumab: 4 of 4 rows · ustekinumab-ttwe (Pyzchiva): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | ustekinumab |
|---|---|
| Dropout rate | —90 mga NCT00307437 · Phase 3 show 44 more results2.2%90 mg NCT00307437 · Phase 3 —45 mg NCT00307437 · Phase 3 1.5%45 mg NCT00307437 · Phase 3 —90 mg NCT00267969 · Phase 3 4.3%90 mg NCT00267969 · Phase 3 —45 mg NCT00267969 · Phase 3 0.4%45 mg NCT00267969 · Phase 3 — NCT02187172 · Phase 4 · registry result, not featured evidence 11.1% NCT01511315 · Phase 4 · registry result, not featured evidence 9.8% NCT01059773 · Phase 4 · registry result, not featured evidence · combination — NCT04435600 · Phase 3 · registry result, not featured evidence —Post Week 28: ABP 654 / ABP 654 NCT04607980 · Phase 3 · registry result, not featured evidence —Post Week 28: ABP 654 Dose Intensi NCT04607980 · Phase 3 · registry result, not featured evidence —Through Week 28: ABP 654 NCT04607980 · Phase 3 · registry result, not featured evidence 4.3%Treatment Group A (ABP 654) NCT04607980 · Phase 3 · registry result, not featured evidence —Ustekinumab Standard Dosage (Long- NCT02698475 · Phase 3 · registry result, not featured evidence —Ustekinumab Standard Dosage (Main NCT02698475 · Phase 3 · registry result, not featured evidence — NCT02203032 · Phase 3 · registry result, not featured evidence —q12w NCT01550744 · Phase 3 · registry result, not featured evidence —subject-tailored fixed-interval NCT01550744 · Phase 3 · registry result, not featured evidence —Half-Standard Dosage NCT01090427 · Phase 3 · registry result, not featured evidence 0%Half-Standard Dosage NCT01090427 · Phase 3 · registry result, not featured evidence —Standard Dosage NCT01090427 · Phase 3 · registry result, not featured evidence 0%Standard Dosage NCT01090427 · Phase 3 · registry result, not featured evidence 1.9%45 mg NCT01008995 · Phase 3 · registry result, not featured evidence —90 mg NCT00723528 · Phase 3 · registry result, not featured evidence 6.5%90 mg NCT00723528 · Phase 3 · registry result, not featured evidence —45 mg NCT00723528 · Phase 3 · registry result, not featured evidence 0%45 mg NCT00723528 · Phase 3 · registry result, not featured evidence —45 mg NCT00747344 · Phase 3 · registry result, not featured evidence 6.6%45 mg NCT00747344 · Phase 3 · registry result, not featured evidence —90 mg NCT00454584 · Phase 3 · registry result, not featured evidence 1.4%90 mg NCT00454584 · Phase 3 · registry result, not featured evidence —45 mg NCT00454584 · Phase 3 · registry result, not featured evidence 3.8%45 mg NCT00454584 · Phase 3 · registry result, not featured evidence —90 mg NCT00320216 · Phase 2 · registry result, not featured evidence 9.4%90 mg NCT00320216 · Phase 2 · registry result, not featured evidence —90 mg weekly for 4 weeks NCT00320216 · Phase 2 · registry result, not featured evidence 9.4%90 mg weekly for 4 weeks NCT00320216 · Phase 2 · registry result, not featured evidence —45 mg NCT00320216 · Phase 2 · registry result, not featured evidence 15.6%45 mg NCT00320216 · Phase 2 · registry result, not featured evidence —45 mg weekly for 4 weeks NCT00320216 · Phase 2 · registry result, not featured evidence 4.7%45 mg weekly for 4 weeks NCT00320216 · Phase 2 · registry result, not featured evidence 14.3% NCT01090063 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | —90 mga NCT00307437 · Phase 3 show 44 more results1.2%90 mg NCT00307437 · Phase 3 —45 mg NCT00307437 · Phase 3 0.5%45 mg NCT00307437 · Phase 3 —90 mg NCT00267969 · Phase 3 0.8%90 mg NCT00267969 · Phase 3 —45 mg NCT00267969 · Phase 3 0%45 mg NCT00267969 · Phase 3 — NCT02187172 · Phase 4 · registry result, not featured evidence — NCT01511315 · Phase 4 · registry result, not featured evidence 0.8% NCT01059773 · Phase 4 · registry result, not featured evidence · combination — NCT04435600 · Phase 3 · registry result, not featured evidence —Post Week 28: ABP 654 / ABP 654 NCT04607980 · Phase 3 · registry result, not featured evidence —Post Week 28: ABP 654 Dose Intensi NCT04607980 · Phase 3 · registry result, not featured evidence —Through Week 28: ABP 654 NCT04607980 · Phase 3 · registry result, not featured evidence 1.1%Treatment Group A (ABP 654) NCT04607980 · Phase 3 · registry result, not featured evidence —Ustekinumab Standard Dosage (Long- NCT02698475 · Phase 3 · registry result, not featured evidence —Ustekinumab Standard Dosage (Main NCT02698475 · Phase 3 · registry result, not featured evidence — NCT02203032 · Phase 3 · registry result, not featured evidence —q12w NCT01550744 · Phase 3 · registry result, not featured evidence —subject-tailored fixed-interval NCT01550744 · Phase 3 · registry result, not featured evidence —Half-Standard Dosage NCT01090427 · Phase 3 · registry result, not featured evidence —Half-Standard Dosage NCT01090427 · Phase 3 · registry result, not featured evidence —Standard Dosage NCT01090427 · Phase 3 · registry result, not featured evidence —Standard Dosage NCT01090427 · Phase 3 · registry result, not featured evidence 1.3%45 mg NCT01008995 · Phase 3 · registry result, not featured evidence —90 mg NCT00723528 · Phase 3 · registry result, not featured evidence 1.6%90 mg NCT00723528 · Phase 3 · registry result, not featured evidence —45 mg NCT00723528 · Phase 3 · registry result, not featured evidence 0%45 mg NCT00723528 · Phase 3 · registry result, not featured evidence —45 mg NCT00747344 · Phase 3 · registry result, not featured evidence 0%45 mg NCT00747344 · Phase 3 · registry result, not featured evidence —90 mg NCT00454584 · Phase 3 · registry result, not featured evidence 0.3%90 mg NCT00454584 · Phase 3 · registry result, not featured evidence —45 mg NCT00454584 · Phase 3 · registry result, not featured evidence 1%45 mg NCT00454584 · Phase 3 · registry result, not featured evidence —90 mg NCT00320216 · Phase 2 · registry result, not featured evidence 0%90 mg NCT00320216 · Phase 2 · registry result, not featured evidence —90 mg weekly for 4 weeks NCT00320216 · Phase 2 · registry result, not featured evidence 3.1%90 mg weekly for 4 weeks NCT00320216 · Phase 2 · registry result, not featured evidence —45 mg NCT00320216 · Phase 2 · registry result, not featured evidence 9.4%45 mg NCT00320216 · Phase 2 · registry result, not featured evidence —45 mg weekly for 4 weeks NCT00320216 · Phase 2 · registry result, not featured evidence 3.1%45 mg weekly for 4 weeks NCT00320216 · Phase 2 · registry result, not featured evidence — NCT01090063 · Phase na · registry result, not featured evidence |
| Serious AEs | 17.8%90 mga NCT00307437 · Phase 3 show 44 more results1.2%90 mg NCT00307437 · Phase 3 19.9%45 mg NCT00307437 · Phase 3 2%45 mg NCT00307437 · Phase 3 13.1%90 mg NCT00267969 · Phase 3 1.6%90 mg NCT00267969 · Phase 3 14.9%45 mg NCT00267969 · Phase 3 0.8%45 mg NCT00267969 · Phase 3 0% NCT02187172 · Phase 4 · registry result, not featured evidence 0% NCT01511315 · Phase 4 · registry result, not featured evidence 8.2% NCT01059773 · Phase 4 · registry result, not featured evidence · combination 0% NCT04435600 · Phase 3 · registry result, not featured evidence 0.4%Post Week 28: ABP 654 / ABP 654 NCT04607980 · Phase 3 · registry result, not featured evidence 4%Post Week 28: ABP 654 Dose Intensi NCT04607980 · Phase 3 · registry result, not featured evidence 2.5%Through Week 28: ABP 654 NCT04607980 · Phase 3 · registry result, not featured evidence —Treatment Group A (ABP 654) NCT04607980 · Phase 3 · registry result, not featured evidence 3.6%Ustekinumab Standard Dosage (Long- NCT02698475 · Phase 3 · registry result, not featured evidence 6.8%Ustekinumab Standard Dosage (Main NCT02698475 · Phase 3 · registry result, not featured evidence 4.5% NCT02203032 · Phase 3 · registry result, not featured evidence 9.2%q12w NCT01550744 · Phase 3 · registry result, not featured evidence 7%subject-tailored fixed-interval NCT01550744 · Phase 3 · registry result, not featured evidence 13.5%Half-Standard Dosage NCT01090427 · Phase 3 · registry result, not featured evidence 2.7%Half-Standard Dosage NCT01090427 · Phase 3 · registry result, not featured evidence 2.8%Standard Dosage NCT01090427 · Phase 3 · registry result, not featured evidence 0%Standard Dosage NCT01090427 · Phase 3 · registry result, not featured evidence 0.6%45 mg NCT01008995 · Phase 3 · registry result, not featured evidence 6.5%90 mg NCT00723528 · Phase 3 · registry result, not featured evidence 4.8%90 mg NCT00723528 · Phase 3 · registry result, not featured evidence 7.8%45 mg NCT00723528 · Phase 3 · registry result, not featured evidence 0%45 mg NCT00723528 · Phase 3 · registry result, not featured evidence 3.4%45 mg NCT00747344 · Phase 3 · registry result, not featured evidence 0%45 mg NCT00747344 · Phase 3 · registry result, not featured evidence 6.4%90 mg NCT00454584 · Phase 3 · registry result, not featured evidence 1.2%90 mg NCT00454584 · Phase 3 · registry result, not featured evidence 6.4%45 mg NCT00454584 · Phase 3 · registry result, not featured evidence 1.9%45 mg NCT00454584 · Phase 3 · registry result, not featured evidence 3.3%90 mg NCT00320216 · Phase 2 · registry result, not featured evidence 1.6%90 mg NCT00320216 · Phase 2 · registry result, not featured evidence 6.5%90 mg weekly for 4 weeks NCT00320216 · Phase 2 · registry result, not featured evidence 4.8%90 mg weekly for 4 weeks NCT00320216 · Phase 2 · registry result, not featured evidence 0%45 mg NCT00320216 · Phase 2 · registry result, not featured evidence 4.8%45 mg NCT00320216 · Phase 2 · registry result, not featured evidence 0%45 mg weekly for 4 weeks NCT00320216 · Phase 2 · registry result, not featured evidence 3.2%45 mg weekly for 4 weeks NCT00320216 · Phase 2 · registry result, not featured evidence 0% NCT01090063 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | 90 mga nasopharyngitis 35% (placebo 7.1%) upper respiratory tract infection 27.1% (placebo 3.4%) arthralgia 14.7% (placebo 2.9%) NCT00307437 · Phase 3 show 42 more results90 mg nasopharyngitis 6.8% (placebo 7.1%) headache 4.6% (placebo 4.1%) upper respiratory tract infection 2.9% (placebo 3.4%) NCT00307437 · Phase 3 45 mg nasopharyngitis 33.7% (placebo 7.1%) upper respiratory tract infection 27.5% (placebo 3.4%) back pain 12.5% (placebo 1.7%) NCT00307437 · Phase 3 45 mg nasopharyngitis 7.3% (placebo 7.1%) headache 4.6% (placebo 4.1%) upper respiratory tract infection 4.4% (placebo 3.4%) NCT00307437 · Phase 3 90 mg upper respiratory tract infection 30.7% (placebo 6.3%) upper respiratory tract infection 30.7% (placebo 6.3%) nasopharyngitis 29.9% (placebo 8.6%) NCT00267969 · Phase 3 90 mg nasopharyngitis 8.2% (placebo 8.6%) upper respiratory tract infection 6.3% (placebo 6.3%) upper respiratory tract infection 6.3% (placebo 6.3%) NCT00267969 · Phase 3 45 mg upper respiratory tract infection 32.2% (placebo 6.3%) upper respiratory tract infection 32.2% (placebo 6.3%) nasopharyngitis 27.5% (placebo 8.6%) NCT00267969 · Phase 3 45 mg nasopharyngitis 10.2% (placebo 8.6%) upper respiratory tract infection 7.1% (placebo 6.3%) upper respiratory tract infection 7.1% (placebo 6.3%) NCT00267969 · Phase 3 upper respiratory infection 50% (placebo 21.1%) common cold 27.3% (placebo 10.5%) anxiety 9.1% (placebo 0%) NCT02187172 · Phase 4 · registry result, not featured evidence nasopharyngitis 23.3% headache 13.5% arthralgia 11% NCT01059773 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 14.3% (placebo 9.5%) headache 10.7% (placebo 4.8%) covid-19 7.1% (placebo 9.5%) NCT04435600 · Phase 3 · registry result, not featured evidence covid-19 9.3% nasopharyngitis 3.6% upper respiratory tract infection 2.4% NCT04607980 · Phase 3 · registry result, not featured evidence covid-19 20% nasopharyngitis 8% proteinuria 8% NCT04607980 · Phase 3 · registry result, not featured evidence nasopharyngitis 2.5% covid-19 2.1% upper respiratory tract infection 2.1% NCT04607980 · Phase 3 · registry result, not featured evidence nasopharyngitis 28.6% arthralgia 10.7% cough 10.7% NCT02698475 · Phase 3 · registry result, not featured evidence nasopharyngitis 25% injection site erythema 13.6% pharyngitis 13.6% NCT02698475 · Phase 3 · registry result, not featured evidence nasopharyngitis 17.3% upper respiratory tract infection 8.3% NCT02203032 · Phase 3 · registry result, not featured evidence q12w upper respiratory tract infection 27.6% nasopharyngitis 9.2% arthralgia 7.9% NCT01550744 · Phase 3 · registry result, not featured evidence subject-tailored fixed-interval upper respiratory tract infection 19.5% nasopharyngitis 15.6% sinusitis 5.6% NCT01550744 · Phase 3 · registry result, not featured evidence Half-Standard Dosage nasopharyngitis 29.7% (placebo 27%) headache 24.3% (placebo 5.4%) upper respiratory tract infection 10.8% (placebo 5.4%) NCT01090427 · Phase 3 · registry result, not featured evidence Half-Standard Dosage nasopharyngitis 13.5% (placebo 27%) headache 10.8% (placebo 5.4%) pharyngitis 8.1% (placebo 0%) NCT01090427 · Phase 3 · registry result, not featured evidence Standard Dosage nasopharyngitis 30.6% (placebo 27%) dysmenorrhoea 8.3% (placebo 0%) upper respiratory tract infection 8.3% (placebo 5.4%) NCT01090427 · Phase 3 · registry result, not featured evidence Standard Dosage headache 8.3% (placebo 5.4%) upper respiratory tract infection 8.3% (placebo 5.4%) diarrhoea 5.6% (placebo 0%) NCT01090427 · Phase 3 · registry result, not featured evidence 45 mg nasopharyngitis 11.9% (placebo 8.1%) upper respiratory tract infection 5.6% (placebo 5%) NCT01008995 · Phase 3 · registry result, not featured evidence 90 mg nasopharyngitis 46.8% (placebo 9.4%) blood creatine phosphokinase increased 19.4% (placebo 3.1%) seasonal allergy 14.5% (placebo 0%) NCT00723528 · Phase 3 · registry result, not featured evidence 90 mg nasopharyngitis 16.1% (placebo 9.4%) eosinophil count increased 6.5% (placebo 3.1%) blood uric acid increased 3.2% (placebo 0%) NCT00723528 · Phase 3 · registry result, not featured evidence 45 mg nasopharyngitis 54.7% (placebo 9.4%) blood triglycerides increased 20.3% (placebo 3.1%) blood creatine phosphokinase increased 17.2% (placebo 3.1%) NCT00723528 · Phase 3 · registry result, not featured evidence 45 mg nasopharyngitis 15.6% (placebo 9.4%) blood triglycerides increased 10.9% (placebo 3.1%) eosinophil count increased 4.7% (placebo 3.1%) NCT00723528 · Phase 3 · registry result, not featured evidence 45 mg nasopharyngitis 13.6% (placebo 5%) hepatic function abnormal 8.5% (placebo 3.3%) upper respiratory tract infection 8.5% (placebo 11.7%) NCT00747344 · Phase 3 · registry result, not featured evidence 45 mg upper respiratory tract infection 11.5% (placebo 11.7%) hyperglycaemia 8.2% (placebo 8.3%) nasopharyngitis 8.2% (placebo 5%) NCT00747344 · Phase 3 · registry result, not featured evidence 90 mg nasopharyngitis 18.4% upper respiratory tract infection 16% back pain 6.4% NCT00454584 · Phase 3 · registry result, not featured evidence 90 mg headache 12.1% nasopharyngitis 9.8% upper respiratory tract infection 6.3% NCT00454584 · Phase 3 · registry result, not featured evidence 45 mg nasopharyngitis 16.7% upper respiratory tract infection 14.2% oropharyngeal pain 5.4% NCT00454584 · Phase 3 · registry result, not featured evidence 45 mg headache 14.8% nasopharyngitis 10% back pain 6.7% NCT00454584 · Phase 3 · registry result, not featured evidence 90 mg upper resp tract infection 14.8% (placebo 20.9%) injury 8.2% (placebo 6%) headache 4.9% (placebo 16.4%) NCT00320216 · Phase 2 · registry result, not featured evidence 90 mg upper resp tract infection 31.3% (placebo 20.9%) headache 18.8% (placebo 16.4%) pain 12.5% (placebo 3%) NCT00320216 · Phase 2 · registry result, not featured evidence 90 mg weekly for 4 weeks upper resp tract infection 11.3% (placebo 20.9%) pain 3.2% (placebo 3%) headache 1.6% (placebo 16.4%) NCT00320216 · Phase 2 · registry result, not featured evidence 90 mg weekly for 4 weeks upper resp tract infection 17.7% (placebo 20.9%) headache 14.5% (placebo 16.4%) nausea 6.5% (placebo 4.5%) NCT00320216 · Phase 2 · registry result, not featured evidence 45 mg upper resp tract infection 16.7% (placebo 20.9%) headache 3.3% (placebo 16.4%) injury 3.3% (placebo 6%) NCT00320216 · Phase 2 · registry result, not featured evidence 45 mg upper resp tract infection 25.4% (placebo 20.9%) headache 19% (placebo 16.4%) pruritus 9.5% (placebo 3%) NCT00320216 · Phase 2 · registry result, not featured evidence 45 mg weekly for 4 weeks upper resp tract infection 8.1% (placebo 20.9%) sinusitis 6.5% (placebo 4.5%) injury 4.8% (placebo 6%) NCT00320216 · Phase 2 · registry result, not featured evidence 45 mg weekly for 4 weeks upper resp tract infection 14.3% (placebo 20.9%) pharyngitis 7.9% (placebo 6%) pruritus 7.9% (placebo 3%) NCT00320216 · Phase 2 · registry result, not featured evidence upper respiratory infection 16.7% acneiform eruption 8.3% NCT01090063 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
ustekinumab
show 29 more results
show 13 more results
show 7 more results
show 3 more results
show 59 more results
show 4 more results
show 2 more results
show 2 more results
+ 28 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ustekinumab's landscape · ustekinumab-ttwe (Pyzchiva)'s landscape